Skip to main content
    C

    Cullinan Oncology LLC (CGEM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.00
    +0.36 (+2.64%)

    Market Cap: $850.89M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(14/23)
    Avg Surprise
    -30.03%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.84
    Range$-1.04 - $-0.71
    9 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.86+2.6%
    60d ago$-0.86+2.6%
    30d ago$-0.85+0.9%
    7d ago$-0.84+0.5%
    Current$-0.84
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.59
    Range$-1.25 - $0.68
    9 analysts
    Revenue Consensus
    $14M
    Range$0 - $104M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.59---
    Sep 26EST
    		-$-0.84---
    Jun 26
    Reported Aug 6
    		$-0.81$-0.71-14.08%Miss+24.3%
    Mar 26
    Reported May 7
    		$-0.75$-0.84+10.71%Beat-1.4%
    Dec 25
    Reported Mar 10
    		$-0.77$-0.87+11.89%Beat-5.5%
    Sep 25
    Reported Nov 6
    		$-0.77$-0.89+13.48%Beat-11.6%
    Jun 25
    Reported Aug 7
    		$-1.07$-0.83-28.92%Miss-42.7%
    Mar 25
    Reported May 8
    		$-0.74$-0.81+8.64%Beat+14.0%
    Dec 24
    Reported Feb 27
    		$-0.73$-0.74+1.66%Beat-35.2%
    Sep 24
    Reported Nov 7
    		$-0.69$-0.77+10.39%Beat+24.2%
    Jun 24
    Reported Aug 8
    		$-0.75$-0.73-2.74%Miss+8.5%
    Mar 24
    Reported May 15
    		$-0.86$-0.99+13.13%Beat+39.4%
    Dec 23
    Reported Mar 14
    		$-0.54$-0.98+44.90%Beat+8.5%
    Sep 23
    Reported Nov 8
    		$-0.91$-0.94+3.19%Beat-68.5%
    Jun 23
    Reported Aug 10
    		$-0.82$-1.00+18.00%Beat-121.8%
    Mar 23
    Reported May 11
    		$-1.42$-0.98-44.90%Miss-425.9%
    Dec 22
    Reported Mar 9
    		$-0.59$-0.71+16.90%Beat+20.3%
    Sep 22
    Reported Nov 14
    		$-0.54$-0.97+44.33%Beat-8.0%
    Jun 22
    Reported Aug 10
    		$3.77$5.42-30.44%Miss+1147.2%
    Mar 22
    Reported May 16
    		$-0.27N/A+50.91%Beat-15782.4%
    Dec 21
    Reported Mar 17
    		$-0.74$-0.47-57.45%Miss+74.1%
    Sep 21
    Reported Nov 9
    		$-0.50$-0.43-16.28%Miss-108.3%
    Jun 21
    Reported Aug 10
    		$-0.36$-0.42+14.29%Beat+64.6%
    Mar 21
    Reported May 14
    		$-0.00N/A-105.67%Miss+99.8%
    Dec 20
    Reported Jan 6
    		$-2.86$-0.38-652.63%Miss-261.8%
    Sep 20
    Reported Nov 2
    		$-0.24$0.00N/AMiss+75.2%
    Jun 20
    Reported Sep 30
    		$-1.02$0.00N/AMiss-20.7%
    Mar 20
    Reported Jun 29
    		$-0.79$0.00N/AMiss+6.3%
    Dec 19
    Reported Mar 30
    		$-0.79$0.00N/AMiss-
    Jun 19
    Reported Sep 30
    		$-0.97$0.00N/AMiss-
    Mar 19
    Reported Jun 29
    		$-0.84$0.00N/AMiss-
    Dec 18
    Reported Mar 30
    		$-0.84$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-4.52EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-50.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio8.42xQuick Ratio8.42x
    Trading Statistics
    Beta-0.04Avg Volume1.25M
    52-Week High$23.1952-Week Low$6.73

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$15.11
    SMA 20$16.12
    SMA 50$19.05
    SMA 200$15.58
    EMA 10$14.94
    EMA 20$16.09
    EMA 50$17.58
    EMA 200$15.66

    MACD

    Line: -1.44Signal: -1.34Hist: -0.11

    ADX

    ADX: 33.5+DI: 16.8-DI: 38.1

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down96.0
    PSAR$16.28

    Bollinger Bands

    Upper Band$20.89
    Lower Band$11.34
    %B Position5924%(Upper)
    Band Width0.28

    RSI (14-Day)

    Neutral
    31.3

    Momentum Oscillators

    Stoch %K6.2
    Stoch %D6.9
    Williams %R-86.9
    ROC (10d)-3.6%
    Momentum-0.53
    CCI (20d)-88.3
    MFI (14d)59.3

    Volatility Measures

    ATR (14d)$1.06(7.6%)
    StdDev (20d)2.39
    Hist Vol95.3%(High)

    Volume Flow

    VWAP$13.88
    OBV20.1M
    AD Line-92.8K
    CMF (20d)-0.198

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.8x
    VWMA (20d)$16.51

    Pivot Points

    R3$14.81
    R2$14.49
    R1$14.07
    Pivot Point$13.75
    S1$13.33
    S2$13.01
    S3$12.59

    Advanced Oscillators

    TSI-35.38
    Ultimate Osc37.8
    KST-265.17

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0$79,000$0$0$0$77,000$0$0$0$77,000$0
    Gross Profit$0$0$-79,000$0$0$0$-77,000$0$0$0$-77,000$0
    Operating Expenses$57.25M$53.70M$55.26M$55.59M$75.80M$55.00M$55.05M$48.85M$50.03M$42.99M$45.48M$44.80M
    R&D$44.44M$42.12M$42.95M$41.97M$61.03M$41.46M$40.49M$35.51M$36.26M$30.65M$34.85M$33.82M
    SG&A$12.82M$11.57M$12.31M$13.63M$14.77M$13.54M$14.56M$13.35M$13.77M$12.34M$10.64M$10.98M
    Operating Income$-57,254,000$-53,697,000$-55,259,000$-55,595,000$-75,798,000$-54,996,000$-55,048,000$-48,855,000$-50,027,000$-42,989,000$-45,485,000$-45,243,000
    Interest Income$3.65M$4.10M$4.62M$5.09M$5.92M$6.58M$7.51M$8.38M$8.07M$5.69M$5.92M$5.88M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-53,704,000$-49,661,000$-50,713,000$-50,610,000$-70,055,000$-48,501,000$-47,530,000$-40,560,000$-42,028,000$-37,340,000$-39,685,000$-39,183,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-53,704,000$-49,661,000$-50,713,000$-50,610,000$-70,055,000$-48,501,000$-47,647,000$-40,560,000$-42,028,000$-37,340,000$-25,563,000$-39,183,000
    EBITDA$-57,273,000$-54,457,000$-56,180,000$-56,982,000$-75,902,000$-57,316,000$-58,476,000$-53,795,000$-53,747,000$-46,263,000$-49,146,000$-44,983,000
    EBIT$-57,352,000$-53,759,000$-55,328,000$-55,703,000$-75,979,000$-55,081,000$-55,042,000$-48,944,000$-50,099,000$-43,033,000$-45,602,000$-45,063,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CGEM

    News

    Price-Driven Insight from (CGEM) for Rule-Based Strategy

    This article provides a price-driven insight for Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting divergent sentiment across all time horizons...

    Stock Traders Daily•10/10/26•Somewhat-Bearish

    BTIG Keeps Their Buy Rating on Cullinan Management (CGEM)

    BTIG analyst Julian Harrison maintained a Buy rating on Cullinan Management (CGEM) with a $40.00 price target. This aligns with a Strong Buy consensus among analysts...

    The Globe and Mail•10/3/26•Bullish

    H.C. Wainwright reiterates Cullinan Oncology stock rating on NDA filing

    H.C. Wainwright reiterated a Buy rating and $35 price target for Cullinan Oncology (NASDAQ: CGEM) after the company announced a rolling NDA submission for zipalertinib in combination with chemotherapy for first-line EGFR...

    Investing.com•10/3/26•Bullish

    Up to $100M hinges on first-line approval as Cullinan (CGEM) starts a lung cancer drug submission.

    Cullinan Therapeutics, Inc. (CGEM) has initiated an FDA New Drug Application (NDA) submission for zipalertinib in combination with chemotherapy for previously untreated non-small cell lung cancer with specific EGFR...

    Stock Titan•10/2/26•Bullish

    H.C. Wainwright reiterates Cullinan Oncology stock rating on NDA filing By Investing.com

    H.C. Wainwright has reaffirmed its Buy rating and $35 price target for Cullinan Oncology Inc. (NASDAQ:CGEM) following the company's announcement of a rolling NDA submission for zipalertinib. The drug...

    Investing.com Nigeria•10/2/26•Bullish

    CGEM Valuation and Fair Value

    P/E
    -4.5x
    Forward P/E
    6.7x
    See GNG's fair value

    CGEM Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -50.3%

    CGEM Competitors

    CompanyTicker
    Alto Neuroscience, Inc.ANRO
    Monte Rosa Therapeutics IncGLUE
    Jade Biosciences, Inc.JBIO
    InMode LtdINMD
    Si-Bone IncSIBN
    P3 Health Partners IncPIII
    Kura Oncology IncKURA
    Ardelyx IncARDX

    Sector: Healthcare

    CGEM Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    1
    Buy
    11
    Hold
    0
    Sell
    0
    Strong Sell
    0

    CGEM Bull Case vs Bear Case

    Bull case

    • CGEM beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 100.0% of CGEM's analyst ratings are Buy or Strong Buy.

    CGEM Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    1.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.84
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About CGEM

    Does CGEM pay dividends?

    Cullinan Oncology LLC (CGEM) does not currently pay a regular dividend.

    What is CGEM's market cap?

    Cullinan Oncology LLC (CGEM) has a market capitalization of $850.89M with a current stock price of $14.00.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In